Tiansheng Pharmaceutical Group Co., Ltd. Stock

Equities

002872

CNE100002QC3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
4.33 CNY -0.92% Intraday chart for Tiansheng Pharmaceutical Group Co., Ltd. +2.36% -15.59%

Financials

Sales 2020 1.2B 166M 227M Sales 2021 737M 102M 139M Capitalization 1.66B 229M 313M
Net income 2020 -491M -67.76M -92.64M Net income 2021 -67M -9.25M -12.64M EV / Sales 2020 1.46 x
Net Debt 2020 255M 35.13M 48.02M Net cash position 2021 6.89M 952K 1.3M EV / Sales 2021 2.24 x
P/E ratio 2020
-3.07 x
P/E ratio 2021
-24.5 x
Employees 1,307
Yield 2020 *
-
Yield 2021
-
Free-Float 53.53%
More Fundamentals * Assessed data
Dynamic Chart
Tiansheng Pharmaceutical Group Co., Ltd. Announces Executive Appointments CI
Tiansheng Pharmaceutical’s Paracetamol Tablet Passes Consistency Test MT
Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tiansheng Pharmaceutical's Technology Center Named National Enterprise Technology Center MT
Tiansheng Pharmaceutical Unit Gets Regulatory Approval for Injection MT
Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chongqing Pharmaceutical CO., LTD. completed the acquisition of 51% stake in Chongqing Changsheng Medicine Co., Ltd. from Tiansheng Pharmaceutical Group Co., Ltd.. CI
Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Tiansheng Pharmaceutical Group Co., Ltd. Approves Election of Directors CI
An unknown buyer acquired 11% stake in Hubei Xianming Medical Apparatus and Instruments Co., Ltd. from Hubei Xianming Medical Apparatus and Instruments Co., Ltd. for CNY 5.1 million. CI
More news
1 day-0.92%
1 week+2.36%
Current month-8.26%
1 month-8.07%
3 months-19.37%
6 months-13.05%
Current year-15.59%
More quotes
1 week
4.12
Extreme 4.12
4.38
1 month
4.03
Extreme 4.03
5.15
Current year
4.03
Extreme 4.03
5.97
1 year
4.03
Extreme 4.03
5.97
3 years
4.03
Extreme 4.03
5.99
5 years
3.61
Extreme 3.61
9.20
10 years
3.61
Extreme 3.61
35.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 31 18-12-05
Director of Finance/CFO 50 -
Director/Board Member 52 20-12-10
Members of the board TitleAgeSince
Director/Board Member 55 18-06-12
Director/Board Member 58 -
Director/Board Member 58 -
More insiders
Date Price Change Volume
24-04-26 4.33 -0.92% 904,750
24-04-25 4.37 +2.82% 1,047,900
24-04-24 4.25 +2.66% 820,150
24-04-23 4.14 +0.49% 765,850
24-04-22 4.12 -2.60% 1,029,059

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Tiansheng Pharmaceutical Group Co LTD is a China-based company principally engaged in the research and development, manufacture and sales of pharmaceuticals. The Company's main products include pediatric lung cough particles, erythromycin enteric-coated capsules, silver ginseng Tongluo capsules, Salvia granules, Shugan Yi spleen granules, compound Ganoderma lucidum granules, Xiangdan injection, Injection, Qi and Diabetes tablets, liver capsule, Ling Jing capsule, lungs of nuclear paste, Shen Qi Yi lung pill, among others. The Company mainly distributes its products within domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002872 Stock